Biohaven Ltd. (BHVN)
20.95
1.11 (5.59%)
At close: Apr 28, 2025, 12:57 PM
5.59% (1D)
| Bid | 20.94 |
| Market Cap | 2.14B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -846.42M |
| EPS (ttm) | -9.28 |
| PE Ratio (ttm) | -2.26 |
| Forward PE | -3.21 |
| Analyst | Buy |
| Ask | 21 |
| Volume | 2,337,429 |
| Avg. Volume (20D) | 1,349,406 |
| Open | 20.24 |
| Previous Close | 19.84 |
| Day's Range | 20.14 - 22.07 |
| 52-Week Range | 15.79 - 55.70 |
| Beta | 4.15 |
About BHVN
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms....
Industry Biotechnology
Sector Healthcare
IPO Date Sep 23, 2022
Employees 256
Stock Exchange NYSE
Ticker Symbol BHVN
Website https://www.biohaven.com/
Analyst Forecast
According to 14 analyst ratings, the average rating for BHVN stock is "Buy." The 12-month stock price forecast is $62, which is an increase of 195.87% from the latest price.
Stock ForecastsNext Earnings Release
Biohaven Ltd. is scheduled to release its earnings on May 12, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
26 minutes ago
Biohaven shares are trading higher after the compa...
Unlock content with
Pro Subscription
3 days ago
-15.21%
Biohaven shares are trading lower after the company announced its withdrawal from a marketing authorization application for Dazluma.
4 days ago · accessnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVNNEW YORK, NY / ACCESS Newswire / April 23, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or the "Company") (NYSE:BHVN).
1 month ago · accessnewswire.com
Shareholder Rights Advocates at Levi & Korsinsky Investigate Biohaven Ltd. (BHVN) Regarding Possible Securities Fraud ViolationsNEW YORK, NY / ACCESS Newswire / March 18, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd. ("Biohaven Ltd.
